In humans, the pathophysiology of metabolic dysfunction-associated steatohepatitis (MASH), that constitutes an advanced stage of MASLD has also been linked to the increased post-prandial release of GIP. This evidence concerns the gene GIP and metabolic dysfunction-associated steatohepatitis.